The safety of RhIG in the prevention of haemolytic disease of the newborn.
Hirose
T G
TG
Department of Pathology and Laboratory Medicine, Good Samaritan Hospital, Los Angeles, CA 90017, USA. tghirosemd@aol.com
Mays
D A
DA
D004899:Erythroblastosis, Fetal / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D012204:Rh-Hr Blood-Group System / Q000276:immunology*; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*; D016896:Treatment Outcome
D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin; C026410:Rho(D) antigen